Cyclooxygenase-2 and prostate carcinogenesis - PubMed (original) (raw)

Review

Cyclooxygenase-2 and prostate carcinogenesis

Tajamul Hussain et al. Cancer Lett. 2003.

Abstract

In recent years a dramatic surge has occurred on studies defining to the role of cyclooxygenase (COX)-2 in causation and prevention of cancer. Prostaglandin (PG) endoperoxidase synthase also commonly referred to as COX is a key enzyme involved in the conversion of arachidonic acid to PGs and other eicosanoids. COX exists as two isoforms, namely COX-1 and COX-2 with distinct tissue distribution and physiological functions. COX-1 is constitutively expressed in many tissues and cell types and is involved in normal cellular physiological functions whereas COX-2 is pro-inflammatory in nature and is inducible by mitogens, cytokines, tumor promoters and growth factors. A large volume of data exists showing that COX-2 is overexpressed in a large number of human cancers and cancer cell lines. The possibility of COX-2 as a candidate player in cancer development and progression evolved from the epidemiological studies which suggest that regular use of aspirin or other non-steroidal anti-inflammatory drugs could significantly decrease the risk of developing cancers in experimental animals and in humans. In our recently published study (Prostate, 42 2000 73-78), we provided the first evidence that COX-2 is overexpressed in human prostate adenocarcinoma. Many other studies verified our initial observation and reported that compared to normal tissue, COX-2 is overexpressed in human prostate cancer. It should be noted that some recent work has suggested that COX-2 is only up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. In this scenario, COX-2 inhibitors could afford their effects against prostate carcinogenesis by modulating COX-2 activity in other cells in prostate. An exciting corollary to this ongoing work is that selective COX-2 inhibitors may exhibit chemopreventive and even chemotherapeutic effects against prostate carcinogenesis in humans.

PubMed Disclaimer

Cited by

The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.
Hillion J, Smail SS, Di Cello F, Belton A, Shah SN, Huso T, Schuldenfrei A, Nelson DM, Cope L, Campbell N, Karikari C, Aderinto A, Maitra A, Huso DL, Resar LM. Hillion J, et al. Pancreatology. 2012 Jul-Aug;12(4):372-9. doi: 10.1016/j.pan.2012.05.005. Epub 2012 May 29. Pancreatology. 2012. PMID: 22898640 Free PMC article.
Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.
Cao B, Chen XP, Zhu P, Ding L, Guan J, Shi ZL. Cao B, et al. World J Gastroenterol. 2008 Nov 28;14(44):6802-7. doi: 10.3748/wjg.14.6802. World J Gastroenterol. 2008. PMID: 19058305 Free PMC article.
Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.
Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A. Veitonmäki T, et al. Br J Cancer. 2014 Sep 23;111(7):1421-31. doi: 10.1038/bjc.2014.381. Epub 2014 Jul 10. Br J Cancer. 2014. PMID: 25010865 Free PMC article.
Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases.
Shankar E, Bhaskaran N, MacLennan GT, Liu G, Daneshgari F, Gupta S. Shankar E, et al. J Urol Res. 2015 Jan 1;2(1):1018. Epub 2015 Jan 12. J Urol Res. 2015. PMID: 26417612 Free PMC article.
Aryl Hydrocarbon Receptor in Oxidative Stress as a Double Agent and Its Biological and Therapeutic Significance.
Grishanova AY, Perepechaeva ML. Grishanova AY, et al. Int J Mol Sci. 2022 Jun 16;23(12):6719. doi: 10.3390/ijms23126719. Int J Mol Sci. 2022. PMID: 35743162 Free PMC article. Review.

Cyclooxygenase-2 and prostate carcinogenesis - PubMed (original) (raw)